- Affordability: a single component to protect against all dengue viruses, instead of a costly multi-valent vaccine.
- Targeting the most conserved structures of the dengue virus.
- No requirement for adjuvants, the platform has its own adjuvanticity.
- A vaccine platform with proved safety in hundreds of volunteers in phase I and II clinical trials for other diseases.
For further information, please visit Isis Innovation Technologies for License.